Wegovy, a weight-loss drug, may carry a higher risk of a blinding condition, referred to as "eye stroke" or vision loss, compared to other GLP-1 drugs. The extent of this risk is unclear, with some reports suggesting it may be up to five times higher. There appears to be a link between weight-loss drugs, including Wegovy, and sudden vision loss, although the details and severity of this connection are still being reported.